Actively Recruiting

Phase 3
Age: 18Years +
All Genders
NCT06904287

Effectiveness of Magnesium in Addition to Prochlorperazine for the Treatment of Migraines

Led by Wake Forest University Health Sciences · Updated on 2026-01-22

100

Participants Needed

1

Research Sites

76 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The purpose of this research study is to find out if using magnesium in addition to prochlorperazine will help reduce your migraine pain.

CONDITIONS

Official Title

Effectiveness of Magnesium in Addition to Prochlorperazine for the Treatment of Migraines

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 218 years or older
  • Able to provide informed consent
  • English speaking
  • Primary diagnosis of migraine with typical migraine features (e.g., recurrent, unilateral, pounding or throbbing headache, associated with nausea) confirmed clinically
Not Eligible

You will not qualify if you...

  • Pregnancy confirmed by positive urine HCG
  • Allergy or sensitivity to study drugs
  • History of renal insufficiency
  • History of myasthenia gravis
  • Use of study drug within 48 hours prior to enrollment
  • Previous participation in this trial during a different encounter

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Advocate Christ Medical Center Emergency Department

Oak Lawn, Illinois, United States, 60453

Actively Recruiting

Loading map...

Research Team

R

Ryan McKillip, MD

CONTACT

M

Marc McDowell, PharmD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here